158 related articles for article (PubMed ID: 8889899)
1. Inhibition of human cytochrome P450-3A isoforms by fluoxetine and norfluoxetine: in vitro and in vivo studies.
Greenblatt DJ; von Moltke LL; Schmider J; Harmatz JS; Shader RI
J Clin Pharmacol; 1996 Sep; 36(9):792-8. PubMed ID: 8889899
[No Abstract] [Full Text] [Related]
2. Sertraline does not inhibit cytochrome P450 3A-mediated drug metabolism in vivo.
Preskorn SH; Alderman J; Greenblatt DJ; Horst WD
Psychopharmacol Bull; 1997; 33(4):659-65. PubMed ID: 9493476
[TBL] [Abstract][Full Text] [Related]
3. Venlafaxine and metabolites are very weak inhibitors of human cytochrome P450-3A isoforms.
von Moltke LL; Duan SX; Greenblatt DJ; Fogelman SM; Schmider J; Harmatz JS; Shader RI
Biol Psychiatry; 1997 Feb; 41(3):377-80. PubMed ID: 9024962
[No Abstract] [Full Text] [Related]
4. Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo.
von Moltke LL; Greenblatt DJ; Duan SX; Harmatz JS; Wright CE; Shader RI
J Clin Psychopharmacol; 1996 Apr; 16(2):104-12. PubMed ID: 8690825
[TBL] [Abstract][Full Text] [Related]
5. Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents.
von Moltke LL; Greenblatt DJ; Schmider J; Duan SX; Wright CE; Harmatz JS; Shader RI
J Clin Pharmacol; 1996 Sep; 36(9):783-91. PubMed ID: 8889898
[TBL] [Abstract][Full Text] [Related]
6. In vitro inhibition of pimozide N-dealkylation by selective serotonin reuptake inhibitors and azithromycin.
Desta Z; Soukhova N; Flockhart DA
J Clin Psychopharmacol; 2002 Apr; 22(2):162-8. PubMed ID: 11910261
[TBL] [Abstract][Full Text] [Related]
7. Use of cytochrome P450 and prolonged prothrombin time.
Liu AC
Am Fam Physician; 1998 Oct; 58(5):1070. PubMed ID: 9787274
[No Abstract] [Full Text] [Related]
8. Serotonin selective reuptake inhibitor drug interactions and the cytochrome P450 system.
Ereshefsky L; Riesenman C; Lam YW
J Clin Psychiatry; 1996; 57 Suppl 8():17-24; discussion 25. PubMed ID: 8698676
[TBL] [Abstract][Full Text] [Related]
9. Effects of antidepressant drugs on the activity of cytochrome P-450 measured by caffeine oxidation in rat liver microsomes.
Danie WA; Syrek M; Ryłko Z; Wójcikowski J
Pol J Pharmacol; 2001; 53(4):351-7. PubMed ID: 11990081
[TBL] [Abstract][Full Text] [Related]
10. Stereoselective inhibition of CYP2C19 and CYP3A4 by fluoxetine and its metabolite: implications for risk assessment of multiple time-dependent inhibitor systems.
Lutz JD; VandenBrink BM; Babu KN; Nelson WL; Kunze KL; Isoherranen N
Drug Metab Dispos; 2013 Dec; 41(12):2056-65. PubMed ID: 23785064
[TBL] [Abstract][Full Text] [Related]
11. The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4'-hydroxylase activity in human liver microsomes.
Kobayashi K; Yamamoto T; Chiba K; Tani M; Ishizaki T; Kuroiwa Y
Br J Clin Pharmacol; 1995 Nov; 40(5):481-5. PubMed ID: 8703653
[TBL] [Abstract][Full Text] [Related]
12. Human cytochromes mediating N-demethylation of fluoxetine in vitro.
von Moltke LL; Greenblatt DJ; Duan SX; Schmider J; Wright CE; Harmatz JS; Shader RI
Psychopharmacology (Berl); 1997 Aug; 132(4):402-7. PubMed ID: 9298519
[TBL] [Abstract][Full Text] [Related]
13. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine.
Scordo MG; Spina E; Dahl ML; Gatti G; Perucca E
Basic Clin Pharmacol Toxicol; 2005 Nov; 97(5):296-301. PubMed ID: 16236141
[TBL] [Abstract][Full Text] [Related]
14. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
Ball SE; Ahern D; Scatina J; Kao J
Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory effect of natural furanocoumarins on human microsomal cytochrome P450 3A activity.
Guo LQ; Taniguchi M; Xiao YQ; Baba K; Ohta T; Yamazoe Y
Jpn J Pharmacol; 2000 Feb; 82(2):122-9. PubMed ID: 10877530
[TBL] [Abstract][Full Text] [Related]
16. Fluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4.
Sager JE; Lutz JD; Foti RS; Davis C; Kunze KL; Isoherranen N
Clin Pharmacol Ther; 2014 Jun; 95(6):653-62. PubMed ID: 24569517
[TBL] [Abstract][Full Text] [Related]
17. Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine.
Zhang H; Coville PF; Walker RJ; Miners JO; Birkett DJ; Wanwimolruk S
Br J Clin Pharmacol; 1997 Mar; 43(3):245-52. PubMed ID: 9088578
[TBL] [Abstract][Full Text] [Related]
18. Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole.
von Moltke LL; Durol AL; Duan SX; Greenblatt DJ
Eur J Clin Pharmacol; 2000 Jun; 56(3):259-61. PubMed ID: 10952482
[TBL] [Abstract][Full Text] [Related]
19. In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors.
Zalma A; von Moltke LL; Granda BW; Harmatz JS; Shader RI; Greenblatt DJ
Biol Psychiatry; 2000 Apr; 47(7):655-61. PubMed ID: 10745059
[TBL] [Abstract][Full Text] [Related]
20. Effect of fluoxetine, norfluoxetine, sertraline and desmethyl sertraline on human CYP3A catalyzed 1'-hydroxy midazolam formation in vitro.
Ring BJ; Binkley SN; Roskos L; Wrighton SA
J Pharmacol Exp Ther; 1995 Dec; 275(3):1131-5. PubMed ID: 8531073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
